USA In August 2000, the Bayer Corporation was granted permission from the city of Berkeley for the development of 14 additional acres south of its present 34-acre site, in the city. Kogenate FS is Bayer Corporation's latest formulation of Factor VIII recombinant protein used to treat haemophilia.
Additional capacity is required to meet the high demand.
The approval to go forward with the development of additional property is a major step in achieving enhanced capacity. It is a significant investment in the company's Berkeley Site, providing Bayer with the opportunity to meet their customers' demands and meet the needs of its growing business. It is the largest building of its type on the West Coast of America. The building contains two mirror image suites, each able to produce a separate product without interruption of the other processes. At maximum capacity, the plant is designed to be able to process four separate products simultaneously.